Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 8/20 | 0.56 |
| ▸ | GID4 | Q8IVV7 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | HTR2B | P41595 | 1/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31062461 | 1.00 | PRCP (0.56) | PRCPGID4GAARECQLSLC22A1 | |
| Hydrochloric Acid SCHEMBL2771890 | 0.98 | PRCP (0.54) | PRCPGID4GAARECQLSLC22A1 | |
| SCHEMBL1038233 | 0.89 | GID4 (0.45) | PRCPGID4GAARECQLHTR2A | |
| SCHEMBL28302626 | 0.82 | GID4 (0.49) | PRCPGID4GAARECQLSLC22A1 | |
| SCHEMBL8813918 | 0.82 | GID4 (0.49) | PRCPGID4GAARECQLSLC22A1 | |
| SCHEMBL4766983 | 0.81 | ALDH1A1 (0.40) | PRCPGID4TSHRMAOAMEN1 | |
| SCHEMBL986611 | 0.81 | PRCP (0.60) | PRCPGID4GAARECQLSLC22A1 | |
| SCHEMBL987517 | 0.81 | PRCP (0.51) | PRCPGID4GAARECQLSLC22A1 | |
| SCHEMBL28485796 | 0.80 | GID4 (0.48) | PRCPGID4GAARECQLSLC22A1 | |
| SCHEMBL5708928 | 0.80 | TAAR1 (0.55) | PRCPGID4HTR2AOPRM1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107163096-B | Troxerutin amide derivative and synthesis method and application thereof | 河南工业大学 | 2020-01-14 | — | — | CN | disclosed |
| US-9255090-B2 | Heterocyclyl derivatives and their use as prostaglandin D2 receptor modulators | ACTELION PHARMACEUTICALS LTD. (CH) | 2016-02-09 | — | — | US | disclosed |
| US-20150252036-A1 | Heterocyclyl Derivatives and their use as Prostaglandin D2 Receptor Modulators | IDORSIA PHARMACEUTICALS LTD (CH) | 2015-09-10 | — | — | US | disclosed |
| US-8575158-B2 | 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin D2 receptor modulators | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-11-05 | — | — | US | disclosed |
| EP-2590944-A1 | 1-PHENYL-SUBSTITUTED HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS | Actelion Pharmaceuticals Ltd. (CH) | 2013-05-15 | — | — | EP | disclosed |
| US-20130109685-A1 | 1-PHENYL-SUBSTITUTED HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-05-02 | — | — | US | disclosed |
| WO-2012004722-A1 | 1-PHENYL-SUBSTITUTED HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS | ACTELION PHARMACEUTICALS LTD (CH) | 2012-01-12 | — | — | WO | disclosed |
| US-8044067-B2 | Isoquinolines as IGF-1R inhibitors | ANALYTECON S.A. (CH) | 2011-10-25 | — | — | US | disclosed |
| US-7875631-B2 | e.g.1-(3,5-dichlorophenyl)-2-formyl-6-methoxy-1,2,3,4-tetrahydroisoquinoline; to prevent and/or treat cancer and other abnormal cell growth, and metabolic as well as blood vessel proliferate disorders, in which uncontrolled expression of insulin-like growth factor-1 receptor is observed | ANALYTECON S.A. (CH) | 2011-01-25 | — | — | US | disclosed |
| US-7842695-B2 | Substituted pyrazole compounds | MERCK PATENT GMBH (DE) | 2010-11-30 | — | — | US | disclosed |
| US-20090099229-A1 | Isoquinolines as IGF-1R Inhibitors | ANALYTECON S.A (CH) | 2009-04-16 | — | — | US | disclosed |
| US-20070129399-A1 | Tetrahydroisoquinoline-and tetrahydrobenzazepine derivatives as igf-1r inhibitors | ANALYTECON S.A. (CH) | 2007-06-07 | — | — | US | disclosed |
| US-20070010531-A1 | Substituted pyrazole compounds | MERCK PATENT GMBH (DE) | 2007-01-11 | — | — | US | disclosed |
| EP-1708999-A1 | BRONCHORELAXING COMPOUNDS | RESPIRATORIUS AB (SE) | 2006-10-11 | — | — | EP | disclosed |
| US-20060040919-A1 | Bronchorelaxing compounds | RESPIRATORIUS AB (SE) | 2006-02-23 | — | — | US | disclosed |
| WO-2005070887-A1 | BRONCHORELAXING COMPOUNDS | RESPIRATORIUS AB (SE) | 2005-08-04 | — | — | WO | disclosed |
| US-6303609-B1 | USED FOR THE INHIBITION OF PLATELET AGGREGATION, AS THROMBOLYTICS, AND/OR FOR THE TREATMENT OF THROMBOEMBOLIC DISORDERS | DUPONT PHARMACEUTICALS COMPANY | 2001-10-16 | — | — | US | disclosed |
| WO-1987005295-A1 | DERIVATIVES OF (NITRO-2 OR AMINO-2 BENZYL)-2 TETRAHYDRO-1,2,3,4 ISOQUINOLEINES, AS WELL AS METHODS FOR OBTAINING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | UNIVERSITE LOUIS PASTEUR (FR) | 1987-09-11 | — | — | WO | disclosed |
| EP-0236251-A2 | 2-(2-aminobenzyl)-1,2,3,4-tetrahydroisoquinolines, processes for obtaining them and pharmaceutical compositions containing them | UNIVERSITE LOUIS PASTEUR (STRASBOURG I) (FR) | 1987-09-09 | — | — | EP | disclosed |
| US-3714171-A | 1-(2-CYCLOHEXYLETHYL) -6 OR 7 METHOXY-1,2,3,4-TETRAHYDROISOQUINOLINE AND ACID ADDITION SALTS THEREOF | TANABE SEIYAKU CO | 1973-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150252036-A1 | Heterocyclyl Derivatives and their use as Prostaglandin D2 Receptor Modulators | PTGDR, PTGER1, PTGDR2 | PRCP 3669/4885GID4 2294/4885GAA 4674/4885 |
| US-20070010531-A1 | Substituted pyrazole compounds | HTR3A, HTR1A, HTR1D | PRCP 2831/4885GID4 3267/4885GAA 4607/4885 |
| US-20130109685-A1 | 1-PHENYL-SUBSTITUTED HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS | PTGER1, PTGDR, PTGDR2 | PRCP 2631/4885GID4 2019/4885GAA 4326/4885 |
| US-20060040919-A1 | Bronchorelaxing compounds | CHRM3, GPR3, CHRM2 | PRCP 3889/4885GID4 4028/4885GAA 4298/4885 |
| US-20070129399-A1 | Tetrahydroisoquinoline-and tetrahydrobenzazepine derivatives as igf-1r inhibitors | IGF1R, INSR, GPR119 | PRCP 3452/4885GID4 275/4885GAA 4179/4885 |
| US-20090099229-A1 | Isoquinolines as IGF-1R Inhibitors | IGF1R, IGFBP1, IGF2BP1 | PRCP 4472/4885GID4 157/4885GAA 3695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.